High Note Wealth LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)

High Note Wealth LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 27.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 8,545 shares of the biopharmaceutical company’s stock after selling 3,209 shares during the period. High Note Wealth LLC’s holdings in Pfizer were worth $246,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Front Street Capital Management Inc. lifted its stake in Pfizer by 4.3% during the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 215 shares during the last quarter. Graves Light Lenhart Wealth Inc. lifted its stake in Pfizer by 1.4% during the second quarter. Graves Light Lenhart Wealth Inc. now owns 19,863 shares of the biopharmaceutical company’s stock valued at $729,000 after purchasing an additional 281 shares during the last quarter. Infrastructure Capital Advisors LLC lifted its stake in Pfizer by 5.2% during the second quarter. Infrastructure Capital Advisors LLC now owns 5,751 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 284 shares during the last quarter. Castleview Partners LLC raised its holdings in shares of Pfizer by 2.4% during the first quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 287 shares during the period. Finally, United Bank raised its holdings in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the topic of a number of recent analyst reports. Barclays cut their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a report on Thursday, December 14th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. UBS Group dropped their price objective on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research note on Thursday, December 14th. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Finally, Truist Financial decreased their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 14th. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Price Performance

Shares of Pfizer stock opened at $27.77 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a fifty-two week low of $25.61 and a fifty-two week high of $42.22. The firm has a fifty day moving average price of $27.47 and a two-hundred day moving average price of $29.47. The company has a market cap of $157.25 billion, a PE ratio of 77.14, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the prior year, the company posted $1.14 EPS. The business’s revenue was down 41.3% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.22 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.